Last updated: 11/04/2018 10:26:17
A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
Trial description: Bioequivalence study to confirm that a NTS with a polyisobutylene (PIB) adhesive from an alternative supplier delivers the same nicotine blood profile as that of the currently approved NTS with a polyisobutylene adhesive from the current supplier.
Primary purpose:
Other
Trial design:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Area under the curve from time 0 to the last quantifiable sample, AUC(0-t)
Timeframe: Baseline to 32 hours
Maximum Measured Plasma Concentration (Cmax)
Timeframe: Baseline to 32 hours
Secondary outcomes:
Area under the concentration time curve between zero and infinity, AUC (0-inf)
Timeframe: Baseline to 32 hours
Time to Maximum Plasma Concentration (Tmax)
Timeframe: Baseline to 32 hours
Plasma half-life (t1/2)
Timeframe: Baseline to 32 hours
Rate of elimination (Kel)
Timeframe: Baseline to 32 hours
Interventions:
Enrollment:
40
Primary completion date:
2012-31-03
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
- BMI 19-27 kg/m2
- smokes >10 cigarettes per day for preceeding 6 months
- inability to stop smoking during study
Inclusion and exclusion criteria
Inclusion criteria:
- BMI 19-27 kg/m2
- smokes >10 cigarettes per day for preceeding 6 months
Exclusion criteria:
- inability to stop smoking during study
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2012-31-03
Actual study completion date
2012-31-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website